ILLINI PELLA, INC.

d option and stock awards held by our named executive officers as of December 31, 2024. Each award to each named executive officer is shown separately. All such option awards were fully vested at December 31, 2024. Option Awards Stock Awards Name and Principal Position Number of Securities Underlying Unexercised Options Exercisable Number of Securities Underlying Unexercised Options Unexercisable Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options Option Exercise Price Option Expiration Date Number of Shares or Units of Stock Unvested Market Value of Shares of Units of Stock Unvested Equity Incentive Plan Awards: Number of Unearned Unvested Shares Equity Incentive Plan Awards: Market or Payout Value of Unearned Unvested Shares Jonathan Kaufman, — — 10

m 2024 to 2023 is related to the time devoted to the grant work and subcontractor costs. Operating Expenses Our operating expenses consist of (i) R&D expenses and (ii) general and administrative expenses. Research and Development Expenses R&D costs primarily consist of direct costs associated with consultants and materials, biologic storage, third party CRO costs and contract development and manufacturing expenses, salaries and other personnel-related expenses. R&D costs are expensed as incurred. More specifically, these costs include: ● costs of funding research performed by third parties that conduct R&D and nonclinical and clinical activities on our behalf; 57 ● costs of manufacturing drug supply and drug product; ● costs of conducting nonclinical studies and clinical trials of our prod